Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Chromium Research Needed To Set RDA, FNB Report Concludes

This article was originally published in The Tan Sheet

Executive Summary

Further research on the benefits of chromium supplementation is needed before a Recommended Dietary Allowance for the mineral can be established, the Institute of Medicine's Food & Nutrition Board states in its Dietary Reference Intakes report on micronutrients released Jan. 9.

You may also be interested in...



Chromium Picolinate Proposed UK Advisory “Completely Unjustified” – CRN

The UK Food Standards Agency consumer advisory asking citizens to avoid using chromium picolinate dietary supplements due to the ingredient's possible association with cancer is flawed, the Council for Responsible Nutrition asserts May 13

Chromium Picolinate Proposed UK Advisory “Completely Unjustified” – CRN

The UK Food Standards Agency consumer advisory asking citizens to avoid using chromium picolinate dietary supplements due to the ingredient's possible association with cancer is flawed, the Council for Responsible Nutrition asserts May 13

Chromium Picolinate Proposed UK Advisory “Completely Unjustified” – CRN

The UK Food Standards Agency consumer advisory asking citizens to avoid using chromium picolinate dietary supplements due to the ingredient's possible association with cancer is flawed, the Council for Responsible Nutrition asserts May 13

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS092083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel